Zenas BioPharma Files 8-K on Financials
Ticker: ZBIO · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1953926
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Zenas BioPharma dropped an 8-K on Nov 12, 2025, covering financials. Check it out.
AI Summary
Zenas BioPharma, Inc. filed an 8-K on November 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 852 Winter Street, Suite 250, Waltham, MA.
Why It Matters
This 8-K filing provides investors with an update on Zenas BioPharma's financial performance and operational status, which is crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant new risks.
Key Players & Entities
- Zenas BioPharma, Inc. (company) — Registrant
- November 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 852 Winter Street, Suite 250 (address) — Principal Executive Offices
- Waltham, MA (location) — Principal Executive Offices Location
- 02451 (zip_code) — Principal Executive Offices Zip Code
- 857-271-2954 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on November 12, 2025.
What is the exact name of the company filing this report?
The exact name of the registrant is Zenas BioPharma, Inc.
In which state is Zenas BioPharma, Inc. incorporated?
Zenas BioPharma, Inc. is incorporated in Delaware.
What is the primary business address of Zenas BioPharma, Inc.?
The primary business address is 852 Winter Street, Suite 250, Waltham, MA 02451.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-11-12 07:12:52
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ZBIO The Nasdaq Global Se
Filing Documents
- tm2530850d1_8k.htm (8-K) — 28KB
- tm2530850d1_ex99-1.htm (EX-99.1) — 57KB
- tm2530850d1_ex99-1img001.jpg (GRAPHIC) — 8KB
- 0001104659-25-109737.txt ( ) — 271KB
- zbio-20251112.xsd (EX-101.SCH) — 3KB
- zbio-20251112_lab.xml (EX-101.LAB) — 33KB
- zbio-20251112_pre.xml (EX-101.PRE) — 22KB
- tm2530850d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On November 12, 2025, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on November 12 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENAS BIOPHARMA, INC. By: /s/ Jennifer Fox Name: Jennifer Fox Title: Chief Business Officer and Chief Financial Officer Date: November 12, 2025